{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.66","upperLimit":"4.24","value":"3.09"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"}],"units":"Participants"}],"description":"PFS is defined among the efficacy population as the time from first dose of study drug until either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.\n\nDisease progression is defined as progressive metabolic disease or one of the follow:\n\n* Target node progression.\n* An individual extranodal lesion must be abnormal with length \\>1.5cm and/or increase of length \\>50%.\n* New or clear progression of nonmeasured lesions.\n* Regrowth of previously resolved lesions or new nodes \\>1.5 cm in length.\n* New or recurrent bone marrow involvement.\n\nPFS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.","dispersionType":"95% Confidence Interval","groups":[{"description":"In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:\n\n* Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)\n* Dose Level 2: 30 μg/kg Day 1 Q3W\n* Dose Level 3: 60 μg/kg Day 1 Q3W\n* Dose Level 4: 90 μg/kg Day 1 Q3W\n* Dose Level 5: 120 μg/kg Day 1 Q3W\n* Dose Level 6: 150 μg/kg Day 1 Q3W\n* Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).\n\nIn Part 2 (expansion), participants received intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Parts 1 and 2: ADCT-402"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.","reportingStatus":"POSTED","timeFrame":"Baseline to End of Study (a maximum of 18 months)","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}